CRA Insights

Evidence requirements for orphan drugs

October 4, 2021

CRA’s Life Sciences Practice focuses on global policy, commercialization, and market access issues dedicated to orphan drug issues, including orphan evidence requirements. By building evidence early, orphan drug companies can help support their products and improve global reimbursement. In this video, Tony Bower discusses how to map out and build a patient narrative to tie together different endpoints of the clinical trials.

For more information on how to decide which evidence to collect that is most effective and develop an evidence generation strategy for payers, please contact: Tony Bower tbower@crai.com

Related Capabilities

Meet the authors